A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors

Recruiting

Phase 1

Phase 2

A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid TumorsA Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors

Sponsor:

Seagen Inc.

Code:

NCT06157892

Conditions

Breast Neoplasms

Gastroesophageal Junction Adenocarcinoma

HER2 Low Breast Neoplasms

HER2 Positive Breast Neoplasms

Stomach Neoplasms

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

disitamab vedotin

tucatinib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-04. This information was provided to ClinicalTrials.gov by Seagen Inc. on 2025-03-25.